Overview

Healiva`s mission is to heal life, by offering a portfolio of innovative acute and chronic wound care solutions, which are personalized and affordable. Our approach combines enzyme technology, cell therapies and medical devices. We offer end-to-end offering of wound care solutions. Our multi-pronged approach to become the go-to-provider for all wound care needs – from wound debridement to treatment of severe wounds. 2-3% of the elderly suffer from painful venous/arterial leg ulcers and nearly 25% of diabetics may develop diabetic foot ulcers in their lifetimes. This figure set to rise with the increasing prevalence of contributing factors, including diabetes, advanced age, and obesity. This burden is also borne by healthcare systems, which spend 2% of their budgets on wound management. About ≈60% of chronic wounds remain unhealed. There remains a major gap in the current treatment paradigm. No permanent therapy for non-healing wounds currently exists. A successful regimen can prevent osteomyelitis, hospitalisation, amputation, and even death, allowing patients to re-establish their normal work/life routines. Healiva is targeting key pain-points in the patient care pathway. Our multifaceted customer base encompasses hospitals, medical practitioners, insurance providers and patients. We are developing a unique selling proposition for chronic wounds healing targeting the high cost of care, time to heal, requirements for frequent dressing changes and specialist medical expertise, whilst reducing wounds reoccurrence and accelerating patients’ re-establishment of normal work/life routines. Healiva’s portfolio potentially address the growing un-met need for chronic wound care, which forms part of the global €15.6B wound care market.